RABINOWITZ DANIEL sold $772K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,852 shares of Natera, Inc. (NTRA) at an average of $416.63 ($406.00–$426.34, $0.77M total) across 2 trades over 2026-10-27 to 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Oct 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short-term sentiment assessment.

02

Market read

Insider sale may prompt modest short-term price movement; broader market impact is limited.

03

What to watch

The insider's remaining large stake and the company's recent performance could offset the sell pressure.

Relevance 4/10Novelty 4/10Timing: after-hours filing on 2026-10-29

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Chief Legal Officer Daniel Rabinowitz sold 1,852 shares for $771,602 via a 10b5-1 plan, reducing his stake to 168,221 shares.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

The sale is modest in size but signals possible concerns; however, the amount is small relative to total float.

Market effects

Minimal impact on the broader genetic testing sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale may be routine under a pre-arranged plan and not indicative of company fundamentals.

Key entities

  • Natera, Inc.

    Genetic testing and diagnostics firm.

  • Daniel Rabinowitz

    Chief Legal Officer of Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.